|Mr. Hany Massarany||Chief Exec. Officer, Pres and Director||834.32k||N/A||56|
|Mr. Scott Mendel||Chief Financial Officer||476.53k||N/A||50|
|Mr. Eric Stier||Sr. VP, Gen. Counsel and Sec.||349.89k||N/A||41|
|Ms. Jennifer Williams||Sr. VP of HR||372.14k||N/A||44|
|Mr. Michael Gleeson||Sr. VP of North American Commercial Operations||372.14k||N/A||42|
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. The company provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, and thrombophilia risk test, as well as HCV genotyping test and associated custom manufactured reagents, and 2C19 genotyping test. The company also provides ePlex instrument and RP panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results without any additional steps. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
GenMark Diagnostics, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 9. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 10.